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phosphatase (r  0.44; P  0.008) and AST (r  0.52; P  0.001).
Since liver dysfunction is relatively common after allogeneic
HSCT, it was not possible to determine if elevated AST and
alkaline phosphatase levels were the cause or the consequence of
higher Vori levels. Based on these data, we conclude that trough
Vori levels vary considerably between patients with a small pro-
portion having potentially subtherapeutic levels on standard doses.
We suggest checking serum Vori levels in patients receiving the
drug for conﬁrmed fungal infections. Additionally, patients devel-
oping elevation of AST or alkaline phosphatase on therapy should
also have Vori levels monitored. Vori levels should also be checked
if the drug dose is changed.
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RESULTS OF ONCE DAILY PARENTERAL BUSULFAN (BUSULFEX)
WITH CYCLOPHOSPHAMIDE VERSUS INTERMITTENT DOSING OF
BUSULFAN WITH CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN
FOR ALLOGENEIC TRANSPLANT RECIPIENTS WITH UNDERLYING HE-
MATOLOGICAL MALIGNANCIES AND DISEASES
Mamlouk, K.1, White, M.J.2, Berryman, R.B.2, Fay, J.W.2,
Pineiro, L.A.2, Vance, E.A.2, Agura, E.A.2 1. Baylor University Med-
ical Center, Dallas, TX; 2. Baylor Sammons Cancer Center and Texas
Oncology.P.A., Dallas, TX.
The use of high dose oral busulfan has been a standard treatment
regimen employed in the ﬁeld of blood and marrow transplanta-
tion for over 30 years. The toxicity proﬁle of high dose busulfan
includes hematological, neurological and hepatic dysfunction. At
doses of 16 mg/kg, the hematological toxicity requires stem cell
rescue. Neurologic toxicity is mild, but has led to the routine use
of phenytoin for seizure prophylaxis. The other principal toxicity
of high dose busulfan is hepatic complications, primarily described
as veno-occlusive disease (VOD).
Historically, high dose busulfan has been administered orally
over four days in a QID dosing schedule. The rationale for this
dosing interval was primarily due to the large numbers of tablets
patients had to swallow for a typical dose (i.e. a 70kg person would
have to swallow 560 tablets). Additional concerns due to hepatic
ﬁrst-pass metabolism have been associated with inter-patient vari-
ation in plasma levels.
The initial trials of a parenteral formulation of IV busulfan were
designed to duplicate the oral dosing experience, and it was deter-
mined that 0.8 mg/kg every 6 hours X 16 doses was an equivalent
dosing regimen. However, many transplant centers are exploring
the feasibility of using once daily dosing (3.2 mg/kg daily times 4
days) versus the conventional dosing regimens.
To date, we have enrolled 13 of 20 anticipated patients on an IRB
approved protocol using once daily dosing of IV busulfan. These
patients will be compared to historical controls who received in-
termittent dosing. Pharmacokinetic monitoring is being performed
using the WINNONLIN® program. The primary objectives of
the study are to compare hematopoietic engraftment, incidence
and severity of VOD, interstitial pneumonitis, and seizure occur-
rence during drug administration.
A preliminary analysis of the ﬁrst 10 patients has not demon-
strated any acute toxicities, and only one of the 10 patients has
required a dosage adjustment.
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ELEVATED PLASMA LEVELS OF TACROLIMUS AFTER CONCURRENT USE
OF TACROLIMUS AND VORICONAZOLE IN THE BONE MARROW TRANS-
PLANT SETTING
Cool, R.M., Ippoliti, C., Cuellar, S., Donato, M.L. University of Texas
MD Anderson Cancer Center, Houston, TX.
Voriconazole is a broad-spectrum triazole antifungal agent used
for the prevention and treatment of invasive fungal infections in
high-risk transplant recipients. Azole antifungal agents have been
associated with numerous drug-drug interactions. Voriconazole is
extensively metabolized through the liver via the cytochrome
(CYP) P450 enzyme system. The primary isoenzymes involved are
CYP2C19, CYP2C9 and CYP3A4. Patients undergoing allogeneic
stem cell transplantation at MD Anderson Cancer Center receive
tacrolimus for graft versus host disease prophylaxis, dosed to
achieve therapeutic plasma levels between 5-12 ng/ml. Reports in
the literature have demonstrated the concurrent use of tacrolimus
and voriconazole to result in supra-therapeutic tacrolimus levels in
liver transplant recipients. Supra-therapeutic tacrolimus levels have
been associated with adverse events such as renal failure requiring
hemodialysis and seizures. The primary objective of this study was
to determine the effect of voriconazole on tacrolimus levels in the
bone marrow transplant setting. We performed a retrospective
chart review of 30 bone marrow and stem cell transplant recipients
who received concurrent therapy with voriconazole and tacroli-
mus. Data collected included patient demographics, diagnosis, type
and date of transplant, concomitant medications, and pertinent
laboratory tests (serum creatinine, blood urea nitrogen, liver func-
tion tests, and tacrolimus levels). The dose of voriconazole was as
follows: 200 mg po BID (n  18), 200 mg po QD (n  1), 200 mg
IV q12h (n  4), and 3-4 mg/kg IV q12h (n  7). Preliminary
results reveal that 22 patients (73%) experienced an increase in
plasma levels of tacrolimus, which occurred at a median of 5 days
(range 2-10 days) of concomitant therapy. Over one-half of these
patients had more than a 75% increase in plasma tacrolimus levels
thus requiring a signiﬁcant decrease in tacrolimus dose. Of the 22
patients, 7 (32%) showed mild to moderate elevations in liver
function tests which may have contributed to supra-therapeutic
tacrolimus levels due to the drug’s extensive hepatic metabolism.
While the manufacturer recommends that the tacrolimus dose be
reduced to one-third of the original dose when initiating therapy
with voriconazole in patients already receiving tacrolimus, our
initial results suggest that some patients may require up to a 75%
decrease in tacrolimus dose to avoid supra-therapeutic levels of
tacrolimus and subsequent sequelae.
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RETROSPECTIVE REVIEW OF THERAPY WITH REDUCED DOSE RAS-
BURICASE IN ADULTS WITH HYPERURICEMIA ASSOCIATED WITH MA-
LIGNANCY
Hutcherson, D.A., Sessions, J.K., Mihelic, R.A., Shayani, S.,
Barreras, A.M., Bucur, S.Z., Heffner, L.T., Langston, A.A. Emory
University Hospital, Winship Cancer Institute, Atlanta, GA.
Here we report our institutional experience in the treatment of
malignancy-related hyperuricemia with reduced dose IV ras-
buricase. Eight patients with various underlying diseases (AML(3),
Burkitt’s NHL (2), ALL (1), MDS (1), MM (1) and CLL/Richter’s
transformation (1)) received 9 treatments (6 mg IV over 30 min-
utes) of rasburicase. Rasburicase was given as a single dose except
in one patient who received a second 6 mg dose early during the
chemotherapy cycle for persistent elevated uric acid levels. Another
patient was retreated with their subsequent cycle of chemotherapy
eight days later. The 6 mg doses of rasburicase for each patient
ranged from 0.05 to 0.1 mg/kg. Patient ages ranged from 46-74
years (mean 62) and patients either had developed or were deemed
at high risk for developing renal dysfunction. Pre-treatment uric
acid levels ranged from21 (2 patients) to 8.7 mg/dL (mean14.6
mg/dL) and pre-therapy serum creatinine levels ranged from 9.9 to
1.1 mg/dL (mean 3.3 mg/dL). As part of standard of care for tumor
lysis, all patients received hyperhydration / alkalinization, pro-
phylactic allopurinol and monitoring of uric acid levels. The single
6 mg dose rapidly reduced uric levels to normal limits (8.3). Uric
acid reductions were observed as follows: 21 to 13.0 @ 17.3h
(patient then received a second dose), 21 to 5.3 @ 38.2h, 16.4 to
5.6 @ 10.3h, 15.1 to 3.3 @ 22.5 h, 15.2 to 4.0 @ 12.1h, 14.1 to 6.6
@ 23.8h, 11.1 to 0.9 @ 20.5h, 9.0 to 2.9 @ 11.5h and 8.7 to 1.2 @
32h. We conclude, that a single 6 mg dose of rasburicase is
sufﬁcient to rapidly reduce hyperuricemia of malignancy and pro-
vides adequate and cost-effective treatment for hyperuricemia from
tumor lysis in adults.
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